Morris Plains, N.J., April 6, 2020 - Immunomedics, Inc.(NASDAQ: IMMU) (`Immunomedics` or the `Company`), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that its Board of Directors (Board) has appointed Harout Semerjian as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 16, 2020. Commenting on this appointment, Dr. Behzad Aghazadeh, Executive Chairman of the Board, stated, `I am delighted that Harout has agreed to join us at this critical juncture in the evolution of Immunomedics. He is a seasoned global pharmaceutical leader with a passion for and expertise in oncology. His long and successful track...
|
